Submissions from 2023
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non-small cell lung cancer (NSCLC), Joshua E. Reuss, Sunil G. Gandhi, David R. Spigel, Pasi A. Janne, Luis G. Paz-Ares, Shirish M. Gadgeel, Jyoti D. Patel, Francesco Passiglia, Alexander I. Spira, Martin J. Edelman, George R. Blumenschein, Ardaman Shergill, Timothy F. Burns, Vijeta Bhambhani, Gloria Patrick, Jonathan A. Pachter, Louis J. Denis, and D. Ross Camidge
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study, Dan-yun Ruan, Myung A. Lee, Yanhong Deng, Keun-Wook Lee, Michael Millward, Jaspreet S. Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Xinfang Hou, Shaozhong Wei, Seok J. Huh, Fu-Rong Liu, Xiaoxi Xie, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Gary E. Richardson, and Rui-Hua Xu
Expression of lysine demethylase 5a (Kdm5a) influences tumour aggressiveness in murine pancreatic cancer cells, Nicole Schreiner, Lisa Fahr, Simone Benitz, Quan Zhou, Ahmed Alnatsha, Axel Imhof, Ujjwal Mahajan, Julia Mayerle, and Ivonne Regel
Comprehensive review of patients with hematologic malignancies in a cancer urgent care center: A single center experience, Muhammad A. Shahid, Linda Albusoul, Sruthi Ramanan, Radhika Gutta, Kylie Springer, Courtney M. Rose, and Philip Kuriakose
Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors, Aditi Shastri, Eric J. Feldman, Alexander N. Starodub, Tatyana Feldman, Cristina P. Rodriguez, Zachary D. Epstein-Peterson, Don A. Stevens, Adam J. Olszewski, Auris O. Huen, Pierluigi Porcu, John C. Reneau, Stefan K. Barta, Enrica Marchi, Ahmad H. Mattour, Lauren C. Pinter-Brown, Rachelle Perea, Sean Donohue, Joyoti Dey, Sagar Agarwal, Rahul Karnik, Ashwin Gollerkeri, Jared Gollob, and Stephen D. Smith
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers, Rachna T. Shroff, Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin, Amit Mahipal, Aparna Kalyan, Milind M. Javle, Carol Aghajanian, Benjamin R. Tan, Puneet S. Cheema, Anuj K. Patel, Renuka V. Iyer, Robin K. Kelley, Jaykumar R. Thumar, Anthony B. El-Khoueiry, E. Gabriela Chiorean, Howard S. Hochster, and Philip A. Philip
OA10.03 Assessing Availability and Demand for Patient-Friendly Resources in Lung Cancer Care: The Patient Perspective, E. K. Singh, A. Desai, Fawzi Abu Rous, and J. Feldman
Preliminary Analysis of ATHN 16: Real-World Safety of Eptacog Beta, T. Singleton, S. Acharya, S. Ahuja, L. Amos, D. Bonzo, A. Eason, M. Escobar, C. Knoll, Philip Kuriakose, E. Lagrue, M. Recht, S. Sullivan, D. Quon, and M. Reding
False positive PET scan in patients with treated malignancy following COVID-19 vaccination, Alexander A. Slota, Vrajesh Parmar, Amy M. Weise, and Ding Wang
Trials in progress: Alliance A022104/NRG-GI010-A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer (LARC; the Janus Rectal Cancer trial), Jesse J. Smith, Arvind Dasari, Qian Shi, Julio Garcia-Aguilar, Hanna K. Sanoff, Thomas J. George, Theodore S. Hong, Greg Yothers, Philip A. Philip, Garth D. Nelson, Tareq Al Baghdadi, Olatunji B. Alese, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Ardaman Shergill, Natally Horvat, Paul B. Romesser, and William A. Hall
2365MO Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC), S. Sridhar, P. H. O'Donnell, T. W. Flaig, J. E. Rosenberg, C. J. Hoimes, M. I. Milowsky, S. Srinivas, S. George, R. R. McKay, D. P. Petrylak, P. M. Coelho Barata, Clara Hwang, M. Cruz-Correa, M. Iafolla, M. Mckean, R. Dreicer, S. Brancato, J. J. Lukas, Y. Yu, and H. Moon
Polygenic risk scores in assessing lung cancer susceptibility in non-Hispanic White and Black populations, Matthew R. Trendowski, Chrissy Lusk, Angie Wenzlaff, Christine Neslund-Dudas, Shirish M. Gadgeel, Ayman Soubani, and Ann G. Schwartz
Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/ NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogenactivated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers), Susanna V. Ulahannan, David R. Spigel, Michael S. Lee, Marwan Fakih, Patrick Grierson, Eric Christenson, E. Gabriela Chiorean, Darryl A. Outlaw, Gazala Khan, Chloe E. Atreya, Aparna R. Parikh, Farshid Dayyani, Alexander I. Spira, Scott Kopetz, Andrea J. Bullock, Zhengrong Li, Xiaoying Chen, Hina Patel, Saswati Hazra, and John H. Strickler
Does Implementing Calendars Outlining Inpatient Chemotherapy Schedules in Patient Rooms Improve Patient's Experience?, Kashmira Wani and Vrushali S. Dabak
Comparison of Maintenance Therapy Regimens of Patients Treated for Multiple Myeloma, Kashmira Wani, Radhika Gutta, Aayush Mittal, Maria Jamil, Kylie Springer, and Philip Kuriakose
Impact of Race on Progression-Free Survival and Overall Survival in Patients with Multiple Myeloma, Kashmira Wani, Radhika Gutta, Aayush Mittal, Maria Jamil, Kylie Springer, and Philip Kuriakose
A phase II trial of pevonedistat plus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC), Leah Wells, Angel Qin, John Rice, Shirish M. Gadgeel, Bryan J. Schneider, Nithya Ramnath, Lili Zhao, and Gregory P. Kalemkerian
Modeling Risk of Atrial Fibrillation in Stem Cell Transplant, Min Wu, Rayli Pichardo, Sowjanya Vuyyala, Josephine Emole, Edward Peres, Muneer H. Abidi, Madhulata Reddy, and Shatha Farhan
Submissions from 2022
Racial and gender disparities in next-generation sequencing for pancreatic adenocarcinoma, Fawzi Abu Rous, Sunny R. K Singh, Chun-Hui Lin, Laila M. Poisson, and Gazala Khan
(P44) Is Prophylactic Cranial Irradiation Necessary in Stage I-IIA Small Cell Lung Cancer Patients? A Single Institution Experience, Sondos Alkhatib, Aharon Feldman, Shirish M. Gadgeel, Andrew Popoff, Munther Ajlouni, Michael Simoff, and Benjamin Movsas
1544P Pre-treatment CT radiomics predicts survival in chemo-immunotherapy-treated small cell lung cancer, Joseph Bae, Prateek Prasanna, and Shirish M. Gadgeel
An Unsupervised Autoencoder Developed from Dynamic Contrast-Enhanced (DCE)-MRI Datasets for Classification of Acute Tumor Response in an Animal Model, Hassan Bagher-Ebadian, Tavarekere N. Nagaraja, Glauber Cabral, Katelynn G. Farmer, Olivia Valadie, P. Acharya, Benjamin Movsas, Stephen L. Brown, Indrin J. Chetty, and James R. Ewing
Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer, Z. Bakouny, P. Grover, C. Labaki, J. Awosika, S. Gulati, C. Y. Hsu, M. A. Bilen, O. Eton, L. Fecher, Clara Hwang, H. Khan, R. R. McKay, E. Ruiz, L. Weissmann, M. A. Thompson, D. Shah, J. Warner, Y. Shyr, T. K. Choueiri, and T. Wise-Draper
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS mutation, Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, Gary L. Buchschacher, Autumn Jackson McRee, Joshua K. Sabari, Melissa L. Johnson, Minal A. Barve, Navid Hafez, Karen Velastegui, James G. Christensen, Thian Kheoh, Hirak Der-Torossian, and Igor I. Rybkin
Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study, B. Besse, M. Johnson, S. H. I. Ou, Shirish M. Gadgeel, A. Spira, J. Lin, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, G. D. L. Lopes, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and A. Drilon
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC), Mark E. Burkard, Meredith McKean, Jordi R. Ahnert, Niharika B. Mettu, Jeremy C. Jones, Jamal G. Misleh, Wen W. Ma, Kian-Huat Lim, E. Gabriela Chiorean, Michael J. Pishvaian, Shirish M. Gadgeel, Heidi A. McKean, Brent Kreider, Deb Knoerzer, Anna Groover, Mary L. Varterasian, Jessica A. Box, Caroline Emery, and Ryan J. Sullivan
Utility of interval imaging during neoadjuvant treatment of locoregional breast cancer, Rebecca Chacko, Pin Li, Nayef H. Abdel-Razeq, Manasi Godbole, and Vrushali S. Dabak
DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I/II study, T. Doi, M. Patel, G. S. Falchook, T. Koyama, C. F. Friedman, S. Piha-Paul, M. E. Gutierrez, Raghan Abdul-Karim, M. Awad, D. R. Adkins, S. Takahashi, S. Kadowaki, B. Cheng, N. Ikeda, A. Laadem, N. Yoshizuka, M. Qian, O. Dosunmu, H-T. Arkenau, and M. L. Johnson
Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors, A. Drilon, B. Besse, D. R. Camidge, S. H. I Ou, Shirish M. Gadgeel, M. L. Johnson, A. Calles, M. J. de Miguel, A. I. Spira, E. Felip, G. Lopes, A. J. van der Wekken, Y. Y. Elamin, J. Green, Y. Sun, J. Soglia, V. W. Zhu, and J. J. Lin
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC, Alexander E. Drilon, Mark M. Awad, Shirish M. Gadgeel, Liza C. Villaruz, Joshua K. Sabari, Javier Perez, Christopher Daly, Shraddha Patel, Siyu Li, Frank A. Seebach, Israel Lowy, Heather D. Magnan, and Petra Rietschel
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study, A. Drilon, S. H.I Ou, Shirish M. Gadgeel, M. Johnson, A. Spira, G. Lopes, B. Besse, E. Felip, A. J. van der Wekken, A. Calles, M. J. de Miguel, D. R. Camidge, Y. Elamin, S. Liu, J. Bauman, D. Haggstrom, G. Riley, H. E. Pelish, V. W. Zhu, and J. J. Lin
Does contralateral prophylactic mastectomy improve survival in triple negative breast cancer?, Genevieve A. Fasano, Solange Bayard, Yalei Chen, Jennifer Marti, Rache Simmons, Alexander Swistel, Jessica Bensenhaver, S. David Nathanson, Lindsay Petersen, Erica Proctor, Melissa Davis, and Lisa Newman
Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers, Siqing Fu, Lisle Nabell, Alexander T. Pearson, Rom Leidner, Douglas Adkins, Marshall R. Posner, Jorge J. Nieva, Debra L. Richardson, Agustin Pimentel, Sanjay Goel, Stuart J. Wong, Alan L. Ho, Ari Rosenberg, Matthew H. Taylor, Raghad Abdul-Karim, Corinne Iacobucci, Xiaoping Qing, Kia Katchar, Katia Schlienger, and David G. Pfister
1549TiP DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC), Shirish M. Gadgeel, J. Al-Mondhiry, M. J. Ahn, S. W. Kim, L. Paz-Ares, H. Prenen, M. Boyer, J. G. Bustamanta Alvarez, B. Solomon, S. Huang, M. Minocha, M. Kistler, and N. Hashemi Sadraei
Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD), Shirish M. Gadgeel, J. Gainor, F. Cappuzzo, E. Garralda, D. H. Lee, J. Mazieres, D. W. Kim, V. Zhu, G. Lopes, S. Miller, M. Nowicka, H. Trinh, S. M. Arndorfer, A. Rahman, J. Noe, Q. Zhang, and V. Subbiah
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC, M. C. Garassino, Shirish M. Gadgeel, G. Speranza, E. Felip, E. Esteban Gonzalez, M. Domine Gomez, M. J. Hochmair, S. F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E. B. Garon, T. Kurata, J. E. Gray, P. O. Schwarzenberger, E. Jensen, and D. Rodriguez Abreu
A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203), Ramaswamy Govindan, Mark M. Awad, Shirish M. Gadgeel, Jonathan A. Pachter, Gloria Patrick, and Louis J. Denis
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes, Laura Graham, Edward Green, Joseph J. Park, Olesia Kellezi, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Deepak Kilari, Melissa Clingerman, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Tanya B. Dorff, Andrew J. Armstrong, Rana R. McKay, Ajjai S. Alva, and Michael T. Schweizer
The role of African Duffy-null allele related inflammation on the tumor microenvironment, Yanira Guerra, Rachel Martini, Jessica Bensenhaver, Yalei Chen, Joseph K. Oppong, Ishmael Kyei, Frances S. Aitpillah, Michael O. Adinku, Joseph K. Oppong, Ernest K. Adjei, Aisha Jibril, Baffour Awuah, Mahteme Bekele, Engida Abebe, Kwasi Ankomah, Ernest B. Osei-Bonsu, Kofi K. Gyan, Clayton Yates, Kim Blenman, Olivier Elemento, Lisa Newman, and Melissa B. Davis
A retrospective study of the association of pre-autologous stem cell transplantation disease status with outcomes in patients with multiple myeloma: A single-center study, Radhika Gutta, Nino Balanchivadze, Kashmira Wani, Aroob Sweidan, Kylie Springer, and Philip Kuriakose
A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19, S. Halabi, B. Luo, H. Dzimitrowicz, Clara Hwang, T. M. Wise-Draper, C. Labaki, R. R. McKay, E. Ruiz, C. Rangel-Escareño, D. Farmakiotis, E. A. Griffiths, C. T. Jani, M. Accordino, C. Friese, E. Wulff-Burchfield, M. Puc, P. Yu, U. Topaloglu, S. Mishra, and J. Warner
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), Omid Hamid, Amy Weise, T. M. Kim, M. Mckean, N. Lakhani, J. Crown, J. Kaczmar, K. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Phase 1 study of fianlimab (FIAN), a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab (CEMI) in advanced melanoma (mel), O. Hamid, Amy Weise, Tae Min Kim, Meredith McKean, Nehal J. Lakhani, John Kaczmar, Kyriakos P. Papadopoulos, Shuquan Chen, Jayakumar Mani, Vladimir Jankovic, Glenn Kroog, Tasha Sims, Israel Lowy, and Giuseppe Gullo
790MO Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. A. Mckean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
400P Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel), O. Hamid, Amy Weise, T. M. Kim, M. Mckean, N. Lakhani, J. Crown, J. Kaczmar, K. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Phase 1 study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, plus cemiplimab in advanced melanoma, O. Hamid, Amy Weise, T. M. Kim, M. McKean, N. J. Lakhani, J. Kaczmar, K. P. Papadopoulos, S. Chen, J. Mani, V. Jankovic, G. Kroog, T. Sims, I. Lowy, and G. Gullo
Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors, Melissa L. Johnson, Raghad Abdul-Karim, David Sommerhalder, Navid Hafez, Shining Wang, Cheryl Li, Yuyin Liu, Lili Yang, Sabrina Collins, Xavier Parot, and James F. Strauss
NovelCombination to Enhance the Antitumor Activity ofKRASG12C Targeted Drugs, H. Y. Khan, S. F. Bannoura, A. Aboukameel, Y. Li, M. Al-Hallak, A. Al Sbihi, S. Kim, R. Beydoun, R. M. Mohammad, Y. Landesman, E. Baloglu, W. Senapedis, A. Sukari, M. Nagasaka, Philip A. Philip, B. El-Rayes, A. Shields, and A. S. Azmi
Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study, Vadim S. Koshkin, Guru P. Sonpavde, false Hwang, Begona Mellado, Gareth Tomlinson, Masashi Shimura, Michael J. Chisamore, Maciej Gil, and Yohann Loriot
OA06.06 Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis, A. Kulkarni, C. Hennessy, G. Wislon, V. Ramesh, Clara Hwang, A. Joy, Z. Bakouny, H. Khan, D. Vilar-Compte, R. McKay, C. Jani, J. W. Riess, M. Puc, A. Kasi, S. Berg, D. R. Castillo, B. Hayes-Lattin, W. Hosmer, D. Flora, S. Mishra, B. French, J. Warner, G. Lopes, S. Peters, and N. Duma
43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. S. Hong, R. Shazer, X. Yan, L. Latven, and K. He
A CASE OF T-CELL PROLYMPHOCYTIC LEUKEMIA PRESENTING WITH VAGINAL BLEEDING, Zeinab Nasser, Aula Ramo, and Vrushali Dabak
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results, Nitin Ohri, Shruti Jolly, Benjamin T. Cooper, Rafi Kabarriti, William R. Bodner, Jonathan Klein, Shankar Viswanathan, Elaine Shum, Joshua K. Sabari, Haiying Cheng, Rasim A. Gucalp, Enrico Castellucci, Angel Qin, Shirish M. Gadgeel, and Balazs Halmos
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT), N. Ohri, S. Jolly, B. T. Cooper, R. Kabarriti, W. R. Bodner III, J. Klein, S. Viswanathan, R. Kaufman, E. Shum, J. K. Sabari, H. Cheng, R. Gucalp, E. Castellucci, A. Qin, Shirish M. Gadgeel, and B. Halmos
RACIAL ETHNIC DIFFERENCES IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER WITH IMMUNE CHECKPOINT INHIBITORS: ANALYSIS OF A LARGE REAL-WORLD DATASET, Laura Oswald, L. Robert Gore, Melanie Buhlmann, Naomi Brownstein, Kea Turner, Andreas Saltos, Jhanelle Gray, Shirish M. Gadgeel, Clement Gwede, Susan Vadaparampil, Brian Gonzalez, and Heather Jim
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/ metastatic NSCLC from the Blood First Assay Screening Trial (BFAST), Solange Peters, Shirish M. Gadgeel, Tony S. K Mok, Ernest Nadal, Saadettin Kilickap, Maurice Perol, Jacques Cadranel, Shunichi Sugawara, Chao-Hua Chiu, Mor Moskovitz, Chong-Jen Yu, Tomohiro Tanaka, Rhea Nersesian, Sarah M. Shagan, Margaret Maclennan, Michael Mathisen, Vijay N. S Bhagawati Prasad, Venice R. Archer, and Rafal Dziadziuszko
Financial impact of immunotherapy-related adverse events among inpatient admissions with solid malignancies, Rayli Pichardo, Yazan A. Omar, and Ding Wang
Inpatient complications of immunotherapy-associated colitis in solid malignancies: Real-world data analysis, Rayli Pichardo, Yazan A. Omar, and Ding Wang
Race-specific genomic determinants of therapeutic response in African American NSCLC patients, Amanda Pilling, Pin Li, Kaitlyn Kane, Frank M. Wolf, Anna B. Berry, and Shirish M. Gadgeel
Sentinel Lymph Node Positivity in Clinically Node Negative Breast Cancer Patients After Neoadjuvant Chemotherapy: Opportunities to Defer Intraoperative Frozen Section Analysis, Omar Qutob, Jessica Bensenhaver, Laura L. Susick, Lindsay Petersen, Anna Lehrberg, Fallon Dimaano, and Theresa Schwartz
Is smoking prognostic for advanced metastatic pancreatic cancer (PC) patients undergoing treatment, Aula Ramo, Zeinab Nasser, Mohamad Beidoun, Baha' M. Abbad, Nayef H. Abdel-Razeq, and Gazala Khan
Disparity Outcomes in Patients Undergoing Pancreas Surgery at an Urban Tertiary Care Center, Mariam A. Saad, Kendyll J. Gartrelle, Rupen Shah, Julie Clark, Kyra Langley, Erin Field, Christopher P. Steffes, and David S. Kwon
A single-center analysis of 30- and 90-day post-pancreatectomy complications in patients undergoing neoadjuvant radiation with EBRT versus MRI-guided SBRT, Mariam Saad, Julie Clark, Rupen A. Shah, Farzan Siddiqui, Parag J. Parikh, Kendyll J. Gartrelle, Abdul Kader Natour, Gazala Khan, and David Kwon
Evaluation of Practice Patterns and Outcomes after Implementing SMART for Pancreatic Cancer, Eric Schaff, Parag J. Parikh, Pin Li, Rupen Shah, Gazala Khan, Farzan Siddiqui, Benjamin Movsas, and David Kwon
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non-small cell lung cancer (NSCLC), Alexander I. Spira, David R. Spigel, D. Ross Camidge, Adrianus De Langen, Tae Min Kim, Koichi Goto, Yasir Y. Elamin, Elaine Shum, Karen L. Reckamp, Julia K. Rotow, Sarah B. Goldberg, Shirish M. Gadgeel, Ticiana Leal, Faris Albayya, Sarah Fitzpatrick, Melinda Louie-Gao, Jagan Parepally, Alena Zalutskaya, and Helena A. Yu
Update on a pilot study: Flumeltbi peripheral blood HLAhaploidentical stem cell transplantation with post-transplant cyclophosphamide and bortezomib (Cy2Bor3), Sowjanya Vuyyala, Edward Peres, Klodiana Neme, Nancy Mikulandric, Susan M. Wautelet, Danielle L. Pelland, Nada Zagar, Mary A. Trapp, Scott R. Rohrer, Elizabeth A. Henne, Sarah Szymanski, Josephine Emole, Muneer H. Abidi, and Shatha Farhan
Post-acute sequelae of SARS-CoV-2 infection in patients with cancer, Jeremy L. Warner, David J. Pinato, Sanjay Mishra, Renee M. Saliby, Clara Hwang, Shuchi Gulati, Rana R. McKay, Chris Labaki, Elizabeth A. Griffiths, Chinmay Jani, Peter P. Yu, Andrew J. Portuguese, Matthew Puc, Pamela Egan, Sumit Shah, Anup Kasi, Stephanie A. Berg, Daniel B. Flora, Melissa K. Accordino, and Dimpy P. Shah
IMMUNOTHERAPY INDUCED MYOCARDITIS, Aseel Yaseen and Randa Loutfi
Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts), Zeynep B. Zengin, Nicholas Henderson, Joseph J. Park, Alicia Ali, Clara Hwang, Pedro C. Barata, Mehmet A. Bilen, Laura Graham, Deepak Kilari, Abhishek Tripathi, Matthew Labriola, Shoshana Rothstein, Rohan Garje, Vadim S. Koshkin, Vaibhav G. Patel, Michael T. Schweizer, Andrew J. Armstrong, Rana R. McKay, Ajjai S. Alva, and Tanya B. Dorff
Submissions from 2021
Satisfaction of hem/onc patients with video visits during the COVID-19 pandemic at a tertiary care center in Michigan, Fawzi Abu Rous, Pin Li, Mohamed Elgamal, Hussna Abunafessa, Rebecca Chacko, Sowjanya Vuyyala, Yaser Alkhatib, and Philip Kuriakose
O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup, J. Ajani, F. El Hajbi, D. Cunningham, M. Alsina, P. Thuss-Patience, G. Scagliotti, M. Van den Eynde, Igor Rybkin, L. Shen, K. Kato, S. Kim, S. D'Alonzo, W. Yu, A. Tao, and E. Van Cutsem
1317P Renal toxicity in black patients with non-squamous non-small cell lung cancer treated with combination platinum-pemetrexed-pembrolizumab therapy, Nino Balanchivadze, Zeinab Nasser, Muhammad Shahid, Cortney McKay, Pin Li, Ryann Sohaney, and Shirish M. Gadgeel
P08.04 Comparative Clinical Outcomes Between EGFR Exon20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors, L. Bazhenova, N. Girard, A. Minchom, S. Ou, Shirish M. Gadgeel, J. M. Trigo, S. Viteri, A. Londhe, P. Mahadevia, and J. Bauml
A phase 1b/2 umbrella study of anti-PD-1 sasanlimab in combination with other therapies for patients with stage IIIb/Iv nonsmall cell lung cancer (NSCLC): The landscape 1011 trial in progress, Michael Boyer, Sandip Patel, Thomas Marron, Nick Pavlakis, Sagun Parakh, Shirish Gadgeel, Michael Shafique, Robert Hoyer, D. Ross Camidge, Charles Farber, Ranee Mehra, Tarek Mekhail, Prunella Blinman, Karey Kowalski, Craig Davis, Dmitri Pavlov, Nayra Gad, and Erminia Massarelli
Molecular Biomarker Testing and Targeted Therapy Patterns in Patients with Acute Myelogenous Leukemia (AML) in Community Health Systems in the United States: A Real-World Data Analysis, Francesca Coutinho, Zartash Gul, Anna B. Berry, Michael A. Thompson, Christopher A. Willner, Sowjanya Vuyyala, Haley McCracken, Katherine Geverd, Jeanna Wallenta Law, Frank M. Wolf, Thomas D. Brown, and Philip Kuriakose
1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C, R. Dziadziuszko, S. Peters, Shirish M. Gadgeel, S. M. Shagan, E. Felip, A. Morabito, P. Cheema, M. C. Dols, Z. Andric, C. H. Barrios, M. Yamaguchi, E. Dansin, P. Danchaivijitr, M. Johnson, S. Novello, D. R. Gandara, E. Schleifman, J. Wang, and T. S.K. Mok
1632P At home androgen deprivation therapy for patients with prostate cancer during the COVID-19 pandemic. One center experience, T. Esakia, T. Melkadze, K. Tsiklauri, E. Mariamidze, S. Tsitsilashvili, N. Otkhozoria, M. Abuladze, N. Jokhadze, and Nino Balanchivadze
Pemetrexed and platinum plus pembrolizumab in patients with metastatic non-squamous non-small cell lung cancer by tumor burden at baseline: A post-hoc efficacy analysis of KEYNOTE-189, Shirish Gadgeel, Jhanelle Grey, Maria Teresa Rizzo, Patrick Peterson, Jongseok Kim, and Delvys Rodríguez-Abreu
P10.03 Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors, Shirish M. Gadgeel, M. Izano, C. Sweetnam, Igor Rybkin, M. Hendawi, J. Weese, A. Patel, D. Reding, J. Treisman, A. Stafford, F. Wolf, C. Zhang, and T. Brown
MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC), J. F. Gainor, G. Curigliano, D. W. Kim, D. H. Lee, B. Besse, C. S. Baik, R. C. Doebele, P. Cassier, G. Lopes, D. SW Tan, E. Garralda, L. Paz-Ares, B. C. Cho, Shirish M. Gadgeel, M. Thomas, S. V. Liu, C. Clifford, H. Zhang, C. D. Turner, and V. Subbiah
KRAS mutations in patients with nonsquamous non-small-cell lung cancer: Prevalence and relationship with PD-l1 expression, tumor mutation burden and smoking status, Marina C. Garassino, Delvys Rodriguez-Abreu, Shirish M. Gadgeel, Dariusz M. Kowalski, Kazuo Kasahara, Enriqueta Felip, Yi-Long Wu, Gilberto de Castro, Byoung Chul Cho, Hande Z. Turna, Hidehito Horinouchi, Martin Reck, Rina Hui, Edward B. Garon, Michael Boyer, Tony S. K Mok, Gilberto Lopes, Julie Kobie, Yongjin Li, Mark A. Ayers, Razvan Cristescu, Bin Zhao, M. Catherine Pietanza, and Roy S. Herbst
MA04.07 Comparative Clinical Outcomes for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutations and Common EGFR Mutations, N. Girard, L. Bazhenova, A. Minchom, S. Ou, Shirish M. Gadgeel, J. Trigo, S. Viteri, G. Li, P. Mahadevia, A. Londhe, D. Backenroth, T. Li, and J. M. Bauml
61MO Biomarker analysis of men with enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) + enza in KEYNOTE-199, J. N. Graff, S. Tagawa, C. Hoimes, W. Gerritsen, U. N. Vaishampayan, T. Elliott, Clara Hwang, A. J.T. Tije, A. G. Omlin, R. S. McDermott, R. De Wit, P. Qiu, C. Poehlein, J. Kim, L. Suttner, R. Cristescu, M. J. Marton, C. Schloss, J. S. de Bono, and E. S. Antonarakis
Phase 1 trial of SQ3370 in solid tumors, Alexander Guminski, Ding Wang, Nam Bui, Vivek Bhadri, Madhawa De Silva, Robert Steffner, Nathan A. Yee, Sangeetha Srinivasan, Jose M. Mejia Oneto, M. Wayne Saville, and Vivek Subbiah
Creating PDXs from continental African breast tumors: Addressing racial inequity through science, Evelyn M. Jiagge, Tahra K. Suhan, Jessica M. Bensenhaver, Michele Dziubinski, Joseph K. Oppong, Francis Aitpillah, Awuah Baffour, John D. Carpten, Lisa A. Newman, Sofia D. Merajver, and Max S. Wicha
P10.04 Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis, Leila Khaddour, C. Zhang, Faria Ali, Shirish M. Gadgeel, E. Tadesse, M. Thompson, D. Reding, J. Treisman, A. Berry, M. Izano, C. Sweetnam, A. Stafford, F. Wolf, T. Brown, and Igor Rybkin
A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies, Tae Min Kim, Dok Hyun Yoon, Ahmad Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, and Seok Jin Kim
Combining enadenotucirev and nivolumab increased tumour immune cell infiltration/ activation in patients with microsatellitestable/ instability-low metastatic colorectal cancer in a phase 1 study, David Krige, Marwan Fakih, Lee Rosen, Ding Wang, Wael Harb, Hani Babiker, Jordan Berlin, Gianfranco Di Genova, David Miles, Mark Powell, Minesh Patel, Jo Carter, Richard Brown, and Tom Lillie
CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma, O. Lawal, O. Lupak, I. Udo, and Josephine Emole
1191O MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy, T. A. Leal, D. Berz, Igor I. Rybkin, W. T. Iams, D. Bruno, C. Blakely, A. Spira, M. R. Patel, D. M. Waterhouse, D. Richards, A. Pham, R. Jotte, E. B. Garon, D. Hong, R. Shazer, X. Yan, L. Latven, and K. He
Phase 1 study of mRNA-2752, A lipid nanoparticle encapsulating mRNAs encoding human OX40L/IL-23/IL-36G, for intratumoral (ITU) injection +/-durvalumab in advanced solid tumors and lymphoma, Manish Patel, Antonio Jimeno, Ding Wang, Salomon Stemmer, Todd Bauer, Randy Sweis, Ravit Geva, Shivaani Kummar, Patrick Reagan, Ruth Perets, Patricia LoRusso, Shilpa Gupta, Sima Zacharek, Andressa Laino, Oleg Milberg, Josh Frederick, Sheryl Chen, Stephanie Pascarella, William Randolph, Praveen Aanur, Lisa Johansen, Khanh Do, Robert Meehan, and Ryan Sullivan
961MO Safety, efficacy, immunogenicity of arenavirus-based vectors HB-201 and HB-202 in patients with HPV16+ cancers, M. R. Posner, A. L. Ho, J. Niu, L. Nabell, R. S. Leidner, J. Nieva, D. L. Richardson, A. T. Pearson, Ding Wang, K. Chung, D. R. Adkins, A. Pimentel, S. Wong, C. Lacobucci, X. Qing, K. Katchar, K. Schlienger, I. Matushansky, S. Fu, and D. G. Pfister
KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non-small cell lung cancer (NSCLC) harboring KRASG12C mutation, G. J. Riely, S. H.I. Ou, Igor Rybkin, A. Spira, K. Papadopoulos, J. K. Sabari, M. Johnson, R. S. Heist, L. Bazhenova, M. Barve, J. M. Pacheco, K. Velastegui, C. Cilliers, P. Olson, J. G. Christensen, T. Kheoh, R. C. Chao, and P. A. Janne
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors, Manish R. Sharma, Richard D. Carvajal, Daniel Catenacci, Leisha A. Emens, Glenn J. Hanna, Dejan Juric, Yoon-Koo Kang, Jeeyun Lee, Keun-Wook Lee, Bob T. Li, Kathleen Moore, Mark D. Pegram, Paula R. Pohlmann, Drew Rasco, Alexander Spira, Arielle L. Heeke, Ding Wang, Lawrence Garbo, Sudhir Manda, Jasgit Sachdev, Shelley E. Ackerman, Heidi LeBlanc, David Dornan, Marcin Kowanetz, Michael N. Alonso, Amreen Husain, Edith A. Perez, and Ecaterina I. Dumbrava
Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors, M. R. Sharma, R. D. Carvajal, G. J. Hanna, Y. K. Kang, J. Lee, K. W. Lee, B. T. Li, K. N. Moore, M. Pegram, D. Rasco, A. Spira, Ding Wang, B. A. Weinberg, M. Alonso, L. Fang, A. Husain, M. Kowanetz, E. A. Perez, and E. I. Dumbrava
OA17.04 The Global Impact of COVID-19 on Telehealth and Care for Persons With Thoracic Cancers, M. Smeltzer, B. Bunn, Y. S. Choi, L. Coate, J. Corona-Cruz, A. Drilon, N. Duma, M. Edelman, M. J. Fidler, Shirish M. Gadgeel, Y. Goto, R. Herbst, M. Hesdorffer, K. Higgins, B. Labdi, T. Leal, S. Liu, J. Mazotti, S. Novello, S. Patel, S. Popat, R. Ramirez, K. Reckamp, N. Reguart, R. Soo, A. Tan, J. Wolf, S. Yano, B. Stiles, and A. Baird
P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors, D. R. Spigel, D. Rodríguez-Abreu, F. Cappuzzo, V. Velcheti, A. K. Ganti, D. Johnson, R. Govindan, S. Antonia, B. Besse, M. Altan, M. Edelman, S. Ramalingam, E. Felip, Shirish M. Gadgeel, O. Juan-Vidal, A. Gupta, S. Currie, W. Lin, M. Tagliaferri, and M. Reck
MO01.33 CRESTONE – Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions – A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210), D. Spigel, S. N. Waqar, M. E. Burkard, J. J. Lin, Y. K. Chae, M. A. Socinski, Shirish M. Gadgeel, K. L. Reckamp, S. M. Leland, D. Plessinger, L. Kunkel, J. R. Bauman, G. Otterson, B. Halmos, Ou SH Ignatius, T. Patil, Y. Y. Elamin, and E. S. Kim
Hyperhemolysis Syndrome in SCD Patient: Reminder of a Rare but Life-Threatening Complication of Blood Transfusion, Aroob Sweidan, Sowjanya Vuyyala, Peter Xie, Mohammad Alhyari, Vrushali Dabak, and Zaher K. Otrock
LUMINOS-102: PVSRIPO with or without immune checkpoint blockade in unresectable anti-PD-1 refractory melanoma, Ding Wang, C. Lance Cowey, Evan Pisick, John Kirkwood, Daniel Corum, Shannon R. Morris, Andrea T. Kelly, Jessica Sorrentino, Lori Mixson, Adam Dickinson, W. Garrett Nichols, and Yana G. Najjar
